Flibanserin
drug drugOn this page
Also known as AddyiBIMT 17BIMT 17 BSBIMT-17EctrisFlibanserinaFlibanserine
Summary
Flibanserin (CHEMBL231068) is an approved small-molecule serotonergic agonist (ATC G02CX02) targeting HTR1A and HTR2A; indicated across 3 conditions including mental disorder and prostate adenocarcinoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: G02CX02
- Targets: 2 (HTR1A, HTR2A)
- Indications: 3 conditions
- Clinical trials: 14
- Chemistry: 390.4 Da · C20H21F3N4O
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL231068 |
| Name | Flibanserin |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 6918248 |
| ChEBI | CHEBI:90865 |
| ATC | G02CX02 |
| Molecular formula | C20H21F3N4O |
| Molecular weight | 390.4 |
| InChIKey | PPRRDFIXUUSXRA-UHFFFAOYSA-N |
SMILES: C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F
IUPAC name: 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
ChEBI definition: An N-alkylpiperazine that is 1-[2-(1,3-dihydro-2-oxobenzimidazol-1-yl)ethyl]piperazine in which the remaining amino proton is replaced by a 3-(trifluoromethyl)phenyl group. A multifunctional serotonin agonist and antagonist which is used for the treatment of pre-menopausal women with hypoactive sexual desire disorder.
Pharmacological roles (ChEBI): serotonergic agonist, serotonergic antagonist, antidepressant.
Also known as: Addyi, BIMT 17, BIMT 17 BS, BIMT-17, Ectris, Flibanserin, Flibanserina, Flibanserine, FLIBANSERIN, flibanserin
Patent coverage: 501 distinct patent families (1,629 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,556 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| HTR1A | 5-HT1A receptor | Agonist | 9 | 0% | P08908 |
| HTR2A | 5-HT2A receptor | Antagonist | 7.31 | 0% | P28223 |
Broader ChEMBL bioactivity targets: 14 (assay-derived). Sample: Alpha-2A adrenergic receptor, D(1A) dopamine receptor, Thromboxane A2 receptor, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Mu-type opioid receptor, D(3) dopamine receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Adenosine receptor A3, 5-hydroxytryptamine receptor 1A, Synaptic vesicular amine transporter, Bile salt export pump.
Bioactivity
ChEMBL activities: 10 potent at pChembl ≥ 5 of 16 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| HTR1A | 8.52 | AC50 | 3 | nM | CHEMBL_ACT_25165107 |
| P19327 | 7.93 | Ki | 11.75 | nM | CHEMBL_ACT_1924326 |
| HTR1A | 7.93 | Ki | 11.8 | nM | CHEMBL_ACT_24911828 |
| Q01827 | 7.14 | AC50 | 72 | nM | CHEMBL_ACT_25197368 |
| DRD3 | 6.54 | AC50 | 286 | nM | CHEMBL_ACT_25194605 |
| ADRA1A | 6.41 | AC50 | 391.2 | nM | CHEMBL_ACT_25218920 |
| HTR1A | 6.2 | EC50 | 631 | nM | CHEMBL_ACT_1924417 |
| OPRM1 | 5.88 | AC50 | 1305 | nM | CHEMBL_ACT_25158258 |
| DRD1 | 5.61 | AC50 | 2435 | nM | CHEMBL_ACT_25115293 |
| CHRM1 | 5 | AC50 | 10100 | nM | CHEMBL_ACT_25209451 |
Target pathways
Aggregated over 2 target gene(s): HTR1A, HTR2A.
Top Reactome pathways
8 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Signal Transduction | 2 | HTR1A, HTR2A |
| Signaling by GPCR | 2 | HTR1A, HTR2A |
| Class A/1 (Rhodopsin-like receptors) | 2 | HTR1A, HTR2A |
| Amine ligand-binding receptors | 2 | HTR1A, HTR2A |
| Serotonin receptors | 2 | HTR1A, HTR2A |
| GPCR ligand binding | 2 | HTR1A, HTR2A |
| GPCR downstream signalling | 1 | HTR2A |
| G alpha (q) signalling events | 1 | HTR2A |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| G protein-coupled receptor signaling pathway | 2 |
| G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 2 |
| serotonin receptor signaling pathway | 2 |
| chemical synaptic transmission | 2 |
| positive regulation of cell population proliferation | 2 |
| signal transduction | 2 |
| G protein-coupled serotonin receptor signaling pathway | 2 |
| behavioral fear response | 1 |
| adenylate cyclase-inhibiting serotonin receptor signaling pathway | 1 |
| gamma-aminobutyric acid signaling pathway | 1 |
| regulation of serotonin secretion | 1 |
| regulation of vasoconstriction | 1 |
| adult behavior | 1 |
| exploration behavior | 1 |
| regulation of dopamine metabolic process | 1 |
Indications & clinical
Indications
1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| mental disorder | 4 | MONDO:0005084 | EFO:0000677 |
1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| prostate adenocarcinoma | 2 | MONDO:0005082 | EFO:0000673 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 14.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 9 |
| PHASE2 | 3 |
| PHASE4 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02714049 | PHASE4 | TERMINATED | Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy |
| NCT00277914 | PHASE3 | COMPLETED | Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women |
| NCT00360243 | PHASE3 | COMPLETED | 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA |
| NCT00360529 | PHASE3 | COMPLETED | 24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder |
| NCT00360555 | PHASE3 | COMPLETED | Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder |
| NCT00441558 | PHASE3 | TERMINATED | A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD). |
| NCT00996164 | PHASE3 | COMPLETED | Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder |
| NCT00996372 | PHASE3 | COMPLETED | Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women |
| NCT01057901 | PHASE3 | TERMINATED | Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America |
| NCT01103362 | PHASE3 | TERMINATED | A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder |
| NCT03707340 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors |
| NCT04743934 | PHASE2 | ACTIVE_NOT_RECRUITING | Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer |
| NCT04002661 | PHASE2 | TERMINATED | Hypoactive Sexual Desire Disorder in Males |
| NCT02770768 | Not specified | TERMINATED | Effects of Flibanserin on the Pre- and Post-menopausal Female Brain |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
593 molecules share ≥1 primary target. Top 100 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| DIHYDROERGOTAMINE | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR2A |
| Fidaxomicin | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR2A |
| Pimavanserin | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR2A |
| Propoxyphene | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR2A |
| REGORAFENIB | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR2A |
| ACETOPHENAZINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| ALMOTRIPTAN | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| AMITRIPTYLINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| AMLODIPINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| AMOXAPINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| APOMORPHINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| ARIPIPRAZOLE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| ASENAPINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| AZATADINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| BAZEDOXIFENE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| BEDAQUILINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| BENFLUOREX | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| BENPERIDOL | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| BOSUTINIB | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| BREXPIPRAZOLE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| BROMOCRIPTINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| BROMPERIDOL | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| BUSPIRONE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CABERGOLINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CANDESARTAN CILEXETIL | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CANNABIDIOL | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CARBENOXOLONE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CARIPRAZINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CARVEDILOL | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CHLORHEXIDINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CHLORPROMAZINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CINACALCET | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CINNARIZINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CISAPRIDE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CITALOPRAM | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CLEMASTINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CLOMIPRAMINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CLONIDINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CLOZAPINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CYCLOBENZAPRINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| CYPROHEPTADINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| DAPIPRAZOLE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| DASATINIB | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| DESLORATADINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| DEXCHLORPHENIRAMINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| DIBENZEPIN | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| DIPHENIDOL | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| DOMPERIDONE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| DOXAZOSIN | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| DOXEPIN | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| DULOXETINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| EBASTINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| ERGOTAMINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| FLUPHENAZINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| GENTIAN VIOLET | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| GEPIRONE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| GUANABENZ | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| GUANFACINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| HALOPERIDOL | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| ILOPERIDONE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| IMIPRAMINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| IPRINDOLE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| KETANSERIN | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| LEFLUNOMIDE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| LETERMOVIR | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| LORCASERIN | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| LOXAPINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| LUMATEPERONE TOSYLATE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| LURASIDONE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| MAPROTILINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| MEBEVERINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| MEFLOQUINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| METHYLERGONOVINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| METHYSERGIDE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| MIANSERIN | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| MIRTAZAPINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| NAFTOPIDIL | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| NEBIVOLOL | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| NEFAZODONE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| NORTRIPTYLINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| OLANZAPINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| OLODATEROL | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| OSIMERTINIB | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| OXICONAZOLE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| OXPRENOLOL | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| OXYMETAZOLINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| OXYPERTINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| PAROXETINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| PASIREOTIDE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| PERGOLIDE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| PERHEXILINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| PERPHENAZINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| PHENOXYBENZAMINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| PHENTOLAMINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| PIMOZIDE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| PIPERACETAZINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| PRAMIPEXOLE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| PRENYLAMINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
| PROCHLORPERAZINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR2A |
Related Atlas pages
- Genes: HTR1A, HTR2A
- Indicated for: mental disorder
- In clinical trials for: prostate adenocarcinoma
- Drugs: Dihydroergotamine, Fidaxomicin, Pimavanserin, Propoxyphene, Regorafenib, Acetophenazine, Almotriptan, Amitriptyline, Amlodipine, Amoxapine, Apomorphine, Aripiprazole, Asenapine, Astemizole, Azatadine, Bazedoxifene, Bedaquiline, Benfluorex, Benperidol, Bosutinib, Brexpiprazole, Bromocriptine, Bromperidol, Buspirone, Cabergoline, Candesartan Cilexetil, Cannabidiol, Carbenoxolone, Cariprazine, Carvedilol, Chlorhexidine, Chlorpromazine, Cinacalcet, Cinnarizine, Cisapride, Citalopram, Clemastine, Clomipramine, Clonidine, Clozapine, Cyclobenzaprine, Cyproheptadine, Dapiprazole, Dasatinib, Desloratadine, Dexchlorpheniramine, Dibenzepin, Diphenidol, Domperidone, Doxazosin, Doxepin, Duloxetine, Ebastine, Ergotamine, Fluphenazine, Gepirone, Guanabenz, Guanfacine, Haloperidol, Iloperidone, Imipramine, Iprindole, Ketanserin, Leflunomide, Letermovir, Lorcaserin, Loxapine, Lumateperone Tosylate, Lurasidone, Maprotiline, Mebeverine, Mefloquine, Methylergonovine, Methysergide, Mianserin, Mirtazapine, Naftopidil, Nebivolol, Nefazodone, Nortriptyline, Olanzapine, Olodaterol, Osimertinib, Oxiconazole, Oxprenolol, Oxymetazoline, Oxypertine, Paroxetine, Pasireotide, Pergolide, Perhexiline, Perphenazine, Phenoxybenzamine, Phentolamine, Pimozide, Piperacetazine, Pramipexole, Prenylamine, Prochlorperazine